Carregant...
Reducing the risk of venous thromboembolism using apixaban – patient perspectives and considerations. Should more attention be given to females?
BACKGROUND: New oral anticoagulant agents, such as apixaban, rivaroxaban, dabigatran, or endoxaban, have recently become for patients an alternative option to conventional treatment in the therapy of venous thromboembolism (VTE). Thus, we aimed to review the available information on adverse events (...
Guardat en:
| Publicat a: | Patient Prefer Adherence |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734816/ https://ncbi.nlm.nih.gov/pubmed/26869771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S82484 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|